2025
Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy 48-Week Results From FOREST-HCM
Saberi S, Abraham T, Choudhury L, Barriales-Villa R, Elliott P, Nassif M, Oreziak A, Owens A, Tower-Rader A, Rader F, Garcia-Pavia P, Olivotto I, Coats C, Fifer M, Sherrid M, Solomon S, Watkins H, Heitner S, Jacoby D, Kupfer S, Malik F, Melloni C, Meng L, Wei J, Maron M, Masri A, Committee and Investigators F. Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy 48-Week Results From FOREST-HCM. JACC Heart Failure 2025, 13: 102496. PMID: 40540987, DOI: 10.1016/j.jchf.2025.03.040.Peer-Reviewed Original ResearchLeft ventricular ejection fractionOutflow tract gradientVentricular ejection fractionEjection fractionKansas City Cardiomyopathy Questionnaire-Clinical Summary ScorePeak left ventricular outflow tract gradientLeft ventricular outflow tract gradientMaximum left ventricular wall thicknessSymptomatic obstructive hypertrophic cardiomyopathyLeft atrial volume indexWeeks of follow-upAtrial volume indexObstructive hypertrophic cardiomyopathyFunctional class improvementLeft ventricular wall thicknessBaseline to weekFavorable cardiac remodelingNYHA functional class improvementRelief of obstructionCardiac biomarker levelsVentricular wall thicknessLong-term safetyDrug discontinuationLateral E/eOpen-label
2023
Clinical Penetrance of the Transthyretin V122I Variant in Older Black Patients With Heart Failure: The SCAN‐MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study
Madhani A, Sabogal N, Massillon D, Paul L, Rodriguez C, Fine D, Helmke S, Winburn M, Kurian D, Raiszadeh F, Teruya S, Cohn E, Einstein A, Miller E, Connors L, Maurer M, Ruberg F. Clinical Penetrance of the Transthyretin V122I Variant in Older Black Patients With Heart Failure: The SCAN‐MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study. Journal Of The American Heart Association 2023, 12: e028973. PMID: 37486082, PMCID: PMC10492994, DOI: 10.1161/jaha.122.028973.Peer-Reviewed Original ResearchConceptsATTR-CMHeart failurePrealbumin concentrationsLeft ventricular wall thicknessPhenotypic penetranceHereditary ATTR-CMOlder black patientsAdvanced heart failureV122I variantVentricular wall thicknessProspective multisite studyYears of ageBlack individualsPyrophosphate imagingEchocardiographic parametersUnderdiagnosed causeBlack patientsSelf-identified Black individualsHF controlsClinical penetrancePrevalenceHispanic individualsMultisite studyBlack participantsPatients
2020
Characteristics and Longer-Term Outcomes of Contemporary Patients <18 Years of Age With Hypertrophic Cardiomyopathy
Alashi A, Svensson L, Klein J, Zahka K, Smedira NG, Najm H, Lever HM, Aziz P, Desai MY. Characteristics and Longer-Term Outcomes of Contemporary Patients <18 Years of Age With Hypertrophic Cardiomyopathy. The American Journal Of Cardiology 2020, 140: 110-117. PMID: 33159906, DOI: 10.1016/j.amjcard.2020.10.060.Peer-Reviewed Original ResearchConceptsOrthotopic heart transplantPrimary composite eventsSudden cardiac deathPresence of symptomsZ-scoreFractional shorteningAppropriate internal defibrillator dischargeVentricular outflow tract gradientLeft ventricular wall thicknessLV septal thicknessOutflow tract gradientPrimary composite outcomeAppropriate ICD dischargeComposite primary endpointLV fractional shorteningVentricular wall thicknessHypertrophic cardiomyopathy patientsYears of ageComposite eventsTract gradientHospital deathPrimary endpointComposite outcomeExperienced centersPHC patients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply